SYNACT — SynAct Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK908.29m
- SEK894.99m
Brief: Synact Pharma Gets Proceeds Of SEK 80 Million Through Issue
Brief: Synact Pharma Q3 Pretax Loss Widens To SEK 9.1 Million
Brief: Synact Pharma Announces Positive Interim Phase 2 Data Of AP1189 In Rheumatoid Arthritis
Brief: Synact Pharma Completes Part 1 Of Phase II Trial With AP1189 For Rheumatoid Arthritis
Brief: Synact Pharma Informs About Termination Of Coverage Agreement With Redeye
Brief: SynAct Pharma Q2 Pre-Tax Loss Narrows To SEK 5.9 Mln
Brief: SynAct Pharma Initiates RESOVIR Scientific And Clinical Collaboration To Explore Ap1189 In Viral Infections
Brief: SynAct Pharma Announces Outcome In The Exercise Of Warrants
Brief: Synact Pharma's Clinical Trial Approved By The Danish Medical Agency
Brief: SynAct Pharma Files Patent Application
Brief: SynAct: Initial Data From First Part Of Phase II Study Within RA
Brief: Synact Pharma Applies For Patent For Ap1189 Within Covid-19
Brief: SynAct Pharma Q4 Pretax Loss Narrows To SEK 6.9 Million
Brief: Synact To Report About Phase IIA Of AP1189 In Q2 2020, Not Q1
Brief: SynAct Says Approval From Swedish Medical Product Agency, Swedish Ethical Review Authority On Phase IIa Study With AP1189
Brief: Synact Pharma Carries Out Directed Issue And Fully-Guaranteed Rights Issue
Brief: Synact Pharma Q2 Pre-Tax Loss Narrows To SEK 7.3 Million
Brief: Synact Pharma Secures Bridge Loan Financing Of Around SEK 10 Mln
Brief: SynAct Pharma Q1 Pretax Loss Widens To SEK 4.7 Mln